MA51612A - Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant - Google Patents
Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiantInfo
- Publication number
- MA51612A MA51612A MA051612A MA51612A MA51612A MA 51612 A MA51612 A MA 51612A MA 051612 A MA051612 A MA 051612A MA 51612 A MA51612 A MA 51612A MA 51612 A MA51612 A MA 51612A
- Authority
- MA
- Morocco
- Prior art keywords
- cyclodextrin
- beta
- gelling agent
- bilastin
- ophthalmic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une composition pharmaceutique ophtalmique aqueuse comprenant : a) au moins 0,4 % p/v de bilastine de formule (i) ou d'un sel ou d'un solvate pharmaceutiquement acceptable correspondant, le sel ou le solvate correspondant de bilastine étant complètement dissous dans la composition pharmaceutique ; b) au moins une bêta-cyclodextrine ; et c) au moins un agent gélifiant soluble dans l'eau pharmaceutiquement acceptable ; et le ph étant compris entre 4 et 9, et son utilisation dans le traitement et/ou la prévention d'états médiés par le récepteur de l'histamine h1, tels que des troubles ou des maladies allergiques. L'invention concerne le traitement et/ou la prévention de conjonctivite allergique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18382021 | 2018-01-18 | ||
PCT/EP2019/050433 WO2019141563A1 (fr) | 2018-01-18 | 2019-01-09 | Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant |
Publications (2)
Publication Number | Publication Date |
---|---|
MA51612A true MA51612A (fr) | 2020-11-25 |
MA51612B1 MA51612B1 (fr) | 2021-06-30 |
Family
ID=61017875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA51612A MA51612B1 (fr) | 2018-01-18 | 2019-01-09 | Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant |
Country Status (27)
Country | Link |
---|---|
US (1) | US20210128544A1 (fr) |
EP (2) | EP3915539A1 (fr) |
JP (1) | JP7309729B2 (fr) |
KR (1) | KR102695627B1 (fr) |
CN (1) | CN111727035B (fr) |
AR (1) | AR114216A1 (fr) |
AU (1) | AU2019209214B2 (fr) |
BR (1) | BR112020014265A2 (fr) |
CA (1) | CA3088740A1 (fr) |
CL (1) | CL2020001895A1 (fr) |
CO (1) | CO2020009992A2 (fr) |
CY (1) | CY1124270T1 (fr) |
DK (1) | DK3740191T3 (fr) |
EA (1) | EA202091725A1 (fr) |
ES (1) | ES2878107T3 (fr) |
HR (1) | HRP20211037T1 (fr) |
HU (1) | HUE054594T2 (fr) |
LT (1) | LT3740191T (fr) |
MA (1) | MA51612B1 (fr) |
MX (1) | MX2020007692A (fr) |
PL (1) | PL3740191T3 (fr) |
PT (1) | PT3740191T (fr) |
SA (1) | SA520412443B1 (fr) |
SI (1) | SI3740191T1 (fr) |
TW (1) | TWI833727B (fr) |
UY (1) | UY38055A (fr) |
WO (1) | WO2019141563A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023156559A1 (fr) | 2022-02-17 | 2023-08-24 | Faes Farma, S.A. | Composition de bilastine pour administration parentérale une fois par jour |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1229075B (it) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
ES2048109B1 (es) | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
JP3527256B2 (ja) | 1992-12-09 | 2004-05-17 | ロート製薬株式会社 | 抗アレルギー点眼剤 |
TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
ES2124167B1 (es) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
DE10161149B4 (de) | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
BRPI0215703B8 (pt) | 2002-04-19 | 2021-05-25 | Faes Farma Sa | polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1 |
US20050239745A1 (en) * | 2004-03-03 | 2005-10-27 | Ophthalmic Research Associates, Inc. | Novel topical ophthalmic formulations |
US7247623B2 (en) | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
WO2007047253A2 (fr) | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Formulations pharmaceutiques de cyclodextrines et composes antifongiques de type azole |
CA2648115C (fr) | 2006-03-31 | 2015-03-24 | Vistakon Pharmaceuticals, Llc | Traitements de l'allergie oculaire |
UA94938C2 (ru) * | 2006-03-31 | 2011-06-25 | ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи | Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты) |
CN106038481A (zh) | 2007-06-28 | 2016-10-26 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
CA2754996A1 (fr) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Formulations ophtalmiques de ketotifene et procedes d'utilisation |
TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
CN103110575B (zh) * | 2013-03-07 | 2014-11-05 | 宁夏康亚药业有限公司 | 一种美洛昔康滴眼液及其制备方法和应用 |
WO2014150899A1 (fr) | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Formulations ophtalmiques topiques pour traiter la migraine |
CN103784462A (zh) * | 2014-02-25 | 2014-05-14 | 宋俊智 | 包含比拉斯汀及甾族化合物的药物制剂 |
EP3040334A1 (fr) | 2014-12-29 | 2016-07-06 | Faes Farma, S.A. | Nouveaux dérivés de benzimidazole en tant qu'agents antihistaminiques |
-
2019
- 2019-01-09 PT PT197011547T patent/PT3740191T/pt unknown
- 2019-01-09 JP JP2020539288A patent/JP7309729B2/ja active Active
- 2019-01-09 CN CN201980009293.0A patent/CN111727035B/zh active Active
- 2019-01-09 CA CA3088740A patent/CA3088740A1/fr not_active Abandoned
- 2019-01-09 LT LTEP19701154.7T patent/LT3740191T/lt unknown
- 2019-01-09 AU AU2019209214A patent/AU2019209214B2/en active Active
- 2019-01-09 MX MX2020007692A patent/MX2020007692A/es unknown
- 2019-01-09 EP EP21169956.6A patent/EP3915539A1/fr not_active Withdrawn
- 2019-01-09 SI SI201930076T patent/SI3740191T1/sl unknown
- 2019-01-09 EP EP19701154.7A patent/EP3740191B1/fr active Active
- 2019-01-09 HU HUE19701154A patent/HUE054594T2/hu unknown
- 2019-01-09 EA EA202091725A patent/EA202091725A1/ru unknown
- 2019-01-09 BR BR112020014265-4A patent/BR112020014265A2/pt unknown
- 2019-01-09 WO PCT/EP2019/050433 patent/WO2019141563A1/fr active Application Filing
- 2019-01-09 US US16/963,219 patent/US20210128544A1/en active Pending
- 2019-01-09 PL PL19701154T patent/PL3740191T3/pl unknown
- 2019-01-09 KR KR1020207023573A patent/KR102695627B1/ko active IP Right Grant
- 2019-01-09 ES ES19701154T patent/ES2878107T3/es active Active
- 2019-01-09 DK DK19701154.7T patent/DK3740191T3/da active
- 2019-01-09 MA MA51612A patent/MA51612B1/fr unknown
- 2019-01-17 AR ARP190100094A patent/AR114216A1/es not_active Application Discontinuation
- 2019-01-17 TW TW108101861A patent/TWI833727B/zh active
- 2019-01-18 UY UY38055A patent/UY38055A/es unknown
-
2020
- 2020-07-15 SA SA520412443A patent/SA520412443B1/ar unknown
- 2020-07-17 CL CL2020001895A patent/CL2020001895A1/es unknown
- 2020-08-13 CO CONC2020/0009992A patent/CO2020009992A2/es unknown
-
2021
- 2021-06-25 CY CY20211100569T patent/CY1124270T1/el unknown
- 2021-06-30 HR HRP20211037TT patent/HRP20211037T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA45020B1 (fr) | Dérivés sulfonamides aromatiques | |
BRPI0408690A (pt) | composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto | |
MA30405B1 (fr) | Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
MA29692B1 (fr) | Derives de la xanthine en tant qu'agonistes selectifs du hm74a | |
TNSN98082A1 (fr) | DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A. | |
MA35070B1 (fr) | Traitements ophtalmiques | |
MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
MA27728A1 (fr) | Antagonistes des recepteurs de cgrp | |
BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
MA28237A1 (fr) | Composition pharmaceutique de vinflunine destinee a une administration parenterale, procede de preparation et utilisation | |
MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
MA51612A (fr) | Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant | |
MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
MA27657A1 (fr) | Derives substitues du 3-(benzoylureido) thiophene, leur procede de preparation et leur utilisation | |
MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
MA50979B1 (fr) | Application de totarol et composition pharmaceutique contenant du totarol | |
EA202090965A1 (ru) | Водные композиции биластина | |
MA52220B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs |